Strategies for successful vaccination against hepatocellular carcinoma. (Articolo in rivista)

Type
Label
  • Strategies for successful vaccination against hepatocellular carcinoma. (Articolo in rivista) (literal)
Anno
  • 2009-01-01T00:00:00+01:00 (literal)
Alternative label
  • Rinaldi, M 1; Iurescia, S 1; Fioretti, D 1; Ponzetto, A 2; Carloni, G 1 (2009)
    Strategies for successful vaccination against hepatocellular carcinoma.
    in International journal of immunopathology and pharmacology
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Rinaldi, M 1; Iurescia, S 1; Fioretti, D 1; Ponzetto, A 2; Carloni, G 1 (literal)
Pagina inizio
  • 269 (literal)
Pagina fine
  • 277 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni
  • KeyWords Plus: T-CELL RESPONSES; HUMAN ALPHA-FETOPROTEIN; HUMAN DENDRITIC CELLS; LIVER-CANCER; GENE-THERAPY; DNA VACCINATION; IN-VITRO; TUMOR; EXPRESSION; INDUCTION Publisher: BIOLIFE SAS, VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY Web of Science Category: Immunology; Pathology; Pharmacology & Pharmacy Subject Category: Immunology; Pathology; Pharmacology & Pharmacy IDS Number: 463RY ISSN: 0394-6320 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 22 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 2 (literal)
Note
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1. ARTOV, Natl Res Council, Inst Neurobiol & Mol Med, I-00133 Rome, Italy 2. Univ Turin, Dept Internal Med, I-10124 Turin, Italy (literal)
Titolo
  • Strategies for successful vaccination against hepatocellular carcinoma. (literal)
Abstract
  • Current therapies against hepatocellular carcinoma (HCC) are not curative in the majority of patients. In the past, immunotherapy approaches aimed to non-specifically stimulate immune response were quite ineffective. New treatments based on stimulation of specific anti-tumor immune response are currently proposed and appear more promising. Tumor-specific antigens identified in HCC demonstrated immunogenicity both in preclinical and clinical trials. Effectiveness in animal studies raised interest in the clinical applicability of non-specific adoptive immunotherapy that prevented disease recurrence after tumor resection. Dendritic cell (DC)-based tumor vaccines achieved encouraging results, and cellular vaccines based on DCs have already entered clinical trials. Preventive and therapeutic DNA vaccination have been proposed, all based on tumor-associated antigens (TAAs), either modified or not, an example being alpha-fetoprotein (AFP). The concomitant expression of co-stimulatory molecules and cytokines was used to increase tumor immunogenicity. Syngeneic or nude mice models indicated that immunotherapy for HCC could stimulate an anti-tumor T-cell response leading to clinical benefit devoid of significant toxicity. The use of DNA-based vaccination raises exciting possibilities in preventing HCC in high-risk individuals such as those with cirrhosis. Novel immunotherapy strategies may contribute in the future to prevention and treatment of HCC. (literal)
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Autore CNR di
Prodotto
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Insieme di parole chiave di
data.CNR.it